Publication number: 20230295639
Abstract: Polypeptide are disclosed that comprise an amino acid sequence at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-1615, not including any functional domains added fused to the protein (whether N-terminal, C-terminal, or internal), and wherein the 1, 2, 3, 4, or 5 N-terminal and/or C-terminal amino acid residues may be present or absent when considering the percent identity.
Type:
Application
Filed:
January 17, 2023
Publication date:
September 21, 2023
Inventors:
Christoffer NORN, Ivan ANISHCHANKA, David BAKER, Sam PELLOCK, Douglas TISCHER, Hsien-Wei YEH
Publication number: 20230250134
Abstract: Polypeptide inhibitors of SARS-COV-2 are disclosed comprising an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17, 19-21, 23-34 and 100-101, and their use for treating and limiting development of SARS-COV-2 infection.
Type:
Application
Filed:
May 25, 2021
Publication date:
August 10, 2023
Inventors:
Longxing CAO, Brian COVENTRY, Inna GORESHNIK, Lauren MILLER, David BAKER, Lisa KOZODOY, John BOWEN, Lauren CARTER, James Brett CASE, Michael DIAMOND, Natasha EDMAN, Andrew HUNT, Michael Christopher JEWETT, Cassandra Jean OGOHARA, Young-jun PARK, Rashmi RAVICHANDRAN, Lance Joseph STEWART, David VEESLER, Bastian VOGELI, Alexandra C. WALLS, Kejia WU, Scott BOYKEN, George UEDA